Navigation Links
Arno Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/18/2008

FAIRFIELD, N.J., Aug. 18 /PRNewswire-FirstCall/-- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced financial results for the second quarter ended June 30, 2008.

Net loss was $3.8 million, or $0.29 per share, for the three months ended June 30, 2008, compared to $0.5 million, or $0.05 per share, for the same period in 2007. Net loss was $7.5 million, or $0.65 per share, for the six months ended June 30, 2008, compared to $0.8 million, or $0.08 per share, for the same period in 2007. Research and development expenses were $2.1 million and $5.3 million for the three and six months ended June 30, 2008, respectively. General and administrative expenses were $0.7 million and $1.2 million for the three and six months ended June 30, 2008. Cash used in operations was $4.9 million for the six months ended June 30, 2008.

At June 30, 2008, Arno had cash and cash equivalents of $14.4 million compared to $1.6 million on December 31, 2007. The increase in cash is attributed to the net proceeds of approximately $17.8 million resulting from Arno's June 2008 private placement of common stock.

"We are very pleased with the first half of the year results, as we continued to advance our Phase I lead compound AR-67, as well as in-license our two additional compounds AR-12 and AR-42," said Scott Z. Fields, MD, President and Chief Medical Officer of Arno. "With the additional capital from our June 2008 financing, we are excited to further advance the development of our three compounds."

Key Achievements for the Six Months Ended June 30, 2008

-- Expanded our product portfolio by in-licensing AR-12, a PDK1 inhibitor, and AR-42, a Pan-DAC inhibitor which also inhibits the Akt pathway

-- Appointed Arie S. Belldegrun, MD as Chairman of the Board of Directors

-- Appointed Robert I. Falk as member of the Board of Directors

-- Completed priv
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PHILADELPHIA , Sept. 2, 2014  TransCelerate ... developed a recommended approach for protecting personal data ... with researchers, patients and others. The document describes ... personal information from CSRs and other related clinical ... The goal of the TransCelerate CSR ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... 02, 2014 PMG Research, Inc ... clinical research site: PMG Research of Rocky Mount. Effective ... of the clinical research department at Boice-Willis Clinic ... in eastern North Carolina. This new site enhances PMG’s ... in Rocky Mount and the surrounding communities, this brings ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... Cell Technologies, Inc., a leader in adult stem cell research and ... Stemedica,s Scientific Advisory Board. In this capacity, she will help ... and cellular delivery system for burn and wound management. , ... ...
... the American Society of Clinical Oncology (ASCO) annual meeting, May ... at 5:00 p.m. Eastern Time - REDWOOD CITY, Calif., April ... today announced that the QUASAR validation study met its ... II colon cancer patients following surgery, and that the colon ...
... and CAMBRIDGE, Mass., April 14 ( AACR ... Genstruct Inc. , a systems biology company focused ... develop novel therapeutics, molecular diagnostics and patient-specific therapies, today ... one of its top pharmaceutical partners will be presented ...
Cached Biology Technology:Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 2Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 3Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 4Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 4Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting 2
(Date:9/2/2014)... of Human Genetics (ASHG) and the National Human ... Institutes of Health, have named Elizabeth P. Tuck, ... School in Columbus, Ohio, the first ASHG/NHGRI Genetics ... , The Genetics and Education Fellowship is intended ... experience, and network to prepare for a career ...
(Date:9/2/2014)... of Evolutionary Biology study provides evidence that ... diversification. , Investigators argue that the same factor ... Galpagos Islands is also responsible for the linguistic ... barriers that impede interaction between speech communities. Therefore, ... due to a reduction of linguistic contact. , ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2Throwing a loop to silence gene expression 2
... the momentum of,September,s impressive showing at the ePassports EAC ... ) advances its role as the,world,s ePassport leader by ... to advanced second-generation ePassports based on the,Extended Access Control ... "Second-generation ePassports represent the beginning of an evolution that,will ...
... WALNUT CREEK, Calif. The U.S. Department of Energy Joint ... assembly of the soybean (Glycine max) genetic code, making ... new breeding strategies for one of the world,s most ... 70 percent of the world,s edible protein, but also ...
... as an homage to achievement in the field of coral ... link between corals of the Pacific and Atlantic. Dr. Ann ... McNeill of the University of Miami named a new species ... some six million years old after renowned coral reef ...
Cached Biology News:The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 3The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 4DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Isopora or isn't it? 2
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: